Braftovi Mektovi from Array BioPharma won FDA approval in 2018 for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Pfizer acquired Array BioPharma in 2019.
Braftovi Mektovi is an example of a BRAF/MEK inhibitor combination. The BRAF gene supports chemical signaling between the cell’s nuclear and the cell’s exterior. The MEK gene, conversely, guides the process of synthesizing MEK1 protein kinase.
Other examples of BRAF/MEK include Tafinlar (dabrafenib) and Mekinist (trametinib) from Novartis, and Zelboraf (vemurafenib) and Cotellic (cobimetinib) from Plexxikon and Genentech.
Filed Under: Oncology